Malcolm Campbell Memorial Prize 2025 Winner!
Congratulations to Dr Nicolas Guisot of RedxPharma who was presented the Malcolm Campbell Memorial Prize 2025 at the RSC-BMCS / SCI 23rd Medicinal Chemistry Symposium!
Dr Guisot was presented this award on behalf of the team behind the discovery and early development of pirtobrutinib (Jaypirca), the first FDA and EMA approved reversible inhibitor of Bruton’s tyrosine kinase (BTK) for the treatment of mantle cell lymphoma.
The Malcolm Campbell Memorial Prize is awarded biennially by the Biological and Medicinal Chemistry Sector of the Royal Society of Chemistry to commemorate Professor Campbell’s outstanding contributions in a broad range of chemistry and their applications to biomedical science.
